BridgeBio Oncology shows early promise
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
Incyte does TGF-beta differently
Four months after yielding first-in-human data INCA33890 enters phase 3.
ASCO-GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
Christmas oncology roundup
The holiday period included Genmab’s discontinuation of acasunlimab.
The conjugate enthusiasm bypasses Mythic
The private ADC company is being wound down.
Lung toxicity deaths halt ifinatamab
Ideate-Lung02 goes on global clinical hold.
Ringside sends Immunome towards filing
On a cross-trial basis varegacestat beats Ogsiveo.
